Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Astellas Pharma Inc. (ALPMY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Astellas Pharma Inc. is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 15.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.Our latest available data shows that ALPMY has returned about 10.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.8%. This means that Astellas Pharma Inc. is outperforming the sector as a whole this year.Another stock in the Medical sector, BillionToOne (BLLN), has outperformed the sector so far this year. The stock's year-to-date return is 15.1%.The consensus estimate for BillionToOne's current year EPS has increased 612.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).To break things down more, Astellas Pharma Inc. belongs to the Medical - Drugs industry, a group that includes 133 individual companies and currently sits at #146 in the Zacks Industry Rank. On average, this group has lost an average of 5.4% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns. On the other hand, BillionToOne belongs to the Medical - Products industry. This 78-stock industry is currently ranked #150. The industry has moved -24.7% year to date.Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and BillionToOne as they attempt to continue their solid performance.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks